A 'one stone, two birds' approach with mesenchymal stem cells for acute respiratory distress syndrome and Type II diabetes mellitus.
Mogesh SababathyGhayathri RamanathanAbd Rahaman YasminRajesh RamasamyJhi Biau FooDaniel Looi Qi HaoNur-Fazila Saulol HamidPublished in: Regenerative medicine (2023)
This review explores the intricate relationship between acute respiratory distress syndrome (ARDS) and Type II diabetes mellitus (T2DM). It covers ARDS epidemiology, etiology and pathophysiology, along with current treatment trends and challenges. The lipopolysaccharides (LPS) role in ARDS and its association between non-communicable diseases and COVID-19 are discussed. The review highlights the therapeutic potential of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) for ARDS and T2DM, emphasizing their immunomodulatory effects. This review also underlines how T2DM exacerbates ARDS pathophysiology and discusses the potential of hUC-MSCs in modulating immune responses. In conclusion, the review highlights the multidisciplinary approach to managing ARDS and T2DM, focusing on inflammation, oxidative stress and potential therapy of hUC-MSCs in the future.
Keyphrases
- acute respiratory distress syndrome
- mesenchymal stem cells
- umbilical cord
- extracorporeal membrane oxygenation
- mechanical ventilation
- oxidative stress
- immune response
- glycemic control
- bone marrow
- coronavirus disease
- endothelial cells
- stem cells
- cell therapy
- type diabetes
- dna damage
- metabolic syndrome
- intensive care unit
- quality improvement
- risk factors
- dendritic cells
- combination therapy
- diabetic rats
- respiratory syndrome coronavirus